Propanc Biopharma (PPCB) Common Equity (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Common Equity of $10.5 million for Q4 2025, up 351.33% year-over-year from $2.3 million in Q4 2024, and down 27.22% quarter-over-quarter from $14.4 million in Q3 2025.
Propanc Biopharma (PPCB) Common Equity (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Common Equity for 15 consecutive years, with $10.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity rose 351.33% year-over-year to $10.5 million; the TTM figure through Dec 2025 stood at $10.5 million (up 351.33% YoY), while the FY2025 annual figure was $13.9 million, up 467.98% from the prior year.
- Common Equity retreated to $10.5 million in Q4 2025 per PPCB's latest filing, from $14.4 million in the prior quarter.
- Across five years, Common Equity topped out at $18.1 million in Q1 2025 and bottomed at -$4.2 million in Q4 2024.
- Historically, Common Equity has averaged $274647.5 across 5 years, with a median of -$3.0 million in 2022.
- Annual changes were most pronounced in 2024 — Common Equity plunged 37.43% — and 2025, when it soared 589.04%.
- Propanc Biopharma's Common Equity stood at -$2.9 million in 2021, then climbed by 0.5% to -$2.9 million in 2022, then retreated by 22.23% to -$3.6 million in 2023, then declined by 16.7% to -$4.2 million in 2024, then soared by 351.33% to $10.5 million in 2025.
- Business Quant data shows PPCB's Common Equity at $10.5 million in Q4 2025, $14.4 million in Q3 2025, and $13.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 10.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.45 Mn |
| Sep 30, 2025 | 14.36 Mn |
| Jun 30, 2025 | 13.91 Mn |
| Mar 31, 2025 | 18.09 Mn |
| Dec 31, 2024 | -4.16 Mn |
| Sep 30, 2024 | -4.11 Mn |
| Jun 30, 2024 | -3.78 Mn |
| Mar 31, 2024 | -3.70 Mn |
| Dec 31, 2023 | -3.56 Mn |
| Sep 30, 2023 | -2.99 Mn |
| Jun 30, 2023 | -3.12 Mn |
| Mar 31, 2023 | -2.94 Mn |
| Dec 31, 2022 | -2.92 Mn |
| Sep 30, 2022 | -2.77 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -2.93 Mn |
| Sep 30, 2021 | -2.31 Mn |
| Jun 30, 2021 | -3.07 Mn |
| Mar 31, 2021 | -3.00 Mn |